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530Objective: Cardiac surgery requiring cardiopulmonary bypass and cardioplegic arrest leads to myocardial
ischemic and reperfusion injury. Gaseous nitric oxide has been demonstrated to have a myocardial protective
effect following ischemia-reperfusion. We hypothesized that gaseous nitric oxide administered during cardio-
pulmonary bypass would have similar beneficial effects.
Methods: In a prospective, randomized, blinded, placebo-controlled study, children undergoing repair of tetral-
ogy of Fallot received either 20 ppm of gaseous nitric oxide or placebo delivered to the membrane oxygenator
during cardiopulmonary bypass.
Results: A total of 16 children were randomized into 2 equal groups once their parents or guardians had given
written informed consent. No differences were found in age, crossclamp time, cardiopulmonary bypass time, or
methemoglobin between the 2 groups. The group receiving gaseous nitric oxide had a significantly shortened
duration of mechanical ventilation (8.4  7.6 vs 16.3  6.5 hours; P<.05) and intensive care unit length of
stay (53.8 19.7 vs 79.4 37.7 hours; P<.05) compared with the placebo group. The patients had significantly
lower troponin levels at 12, 24, and 48 hours (P<.05) and lower B-type natriuretic peptide levels at 12 and 24
hours (P<.05). A trend was found toward a less positive fluid balance, with significantly less diuretic usage. The
study patients had a greater mean hemoglobin at 48 hours, despite the absence of differences in chest tube output,
packed red blood cell transfusion, platelet counts or transfusion requirements, fresh frozen plasma transfusion,
or prothrombin time/partial thromboplastin time in the first 48 hours.
Conclusions: The delivery of gaseous nitric oxide to the cardiopulmonary bypass circuit for children undergo-
ing cardiac surgery results in myocardial protection, improved fluid balance, and an improved postoperative
intensive care unit course. (J Thorac Cardiovasc Surg 2013;146:530-6)Cardiac surgery requiring cardiopulmonary bypass (CPB)
and cardioplegic arrest leads to myocardial ischemic and re-
perfusion injury. This combination of insults leads to myo-
cardial necrosis in as many as 40% of cardiac surgeries.1
These phenomena cause cardiac, vascular, and pulmonary
dysfunction.2 Central to the pathophysiology of reperfusion
injury is a robust local inflammatory response that contrib-
utes to the CPB-induced systemic inflammatory response.
The responsible cellular and molecular mechanisms are
not completely understood but include complement activa-
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The Journal of Thoracic and Cardiovascular SurgOne major component of this process, and the focus of
the present investigation, is the nitric oxide (NO) pathway.
NO can play several protective roles in the inflammatory
response, ischemia/reperfusion injury, and apoptosis.4 For
example, gaseous NO (gNO) has been demonstrated to
have a myocardial protective effect, primarily by ameliorat-
ing reperfusion injury.5 Additionally, alterations in NO
generation appear to underpin the interrelationship of endo-
thelial function and inflammation.6 Given this evidence,
administration of NO might prove effective in decreasing
the incidence of morbidity after cardiac surgery.
We hypothesized that myocardial ischemia/reperfusion
injury might be modulated through the innovative delivery
of supplemental gNOduringCPB and thus improve the post-
operative course. Our premisewas that gNO delivered to the
circuit allows immediate availability ofNOat themoment of
reperfusion and has effects distal to the entry site. Through
the present randomized, blinded, placebo-controlled trial,
we aimed to determine the effects of supplemental gNO
on ischemia/reperfusion injury, the inflammatory response,
and the resultant end-organ injury after CPB.METHODS
Children undergoing complete repair of tetralogy of Fallot from July
2007 to October 2010 were eligible for participation. The trial wasery c September 2013
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BNP ¼ B-type natriuretic peptide
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University School of Medicine institutional review board approved the
study. The parents or guardians of all patients approved the present study.
The patients were randomized into 1 of 2 groups: group 1, intraoperative
administration of 20 ppm of gNO to the oxygenator of the CPB circuit;
or group 2, placebo gas treatment.
Other than failure to obtain informed consent, the patients potentially
eligible for enrollment were excluded for any of the following reasons:
(1) signs of persistently elevated pulmonary vascular resistance preopera-
tively; (2) cardiac arrest 1 week before surgery; (3) previous surgical pro-
cedure that required the use of CPB; (4) recent treatment with steroids or
condition that might require treatment with steroids, excluding steroid
administration specifically for CPB; and (5) the use of another investiga-
tional drug.
Cardiac surgical procedures were performed at the St. Louis Children’s
Hospital surgical suite. Additional postoperative care and studies were per-
formed in the pediatric cardiac intensive care unit (CICU). The time points
were referenced from the time of admission to the pediatric CICU for both
groups. A standardized anesthetic protocol was used throughout the study
period. The intraoperative measurements included the aortic crossclamp
time and total CPB time. The intraoperative hemodynamic measurements
included the mean arterial blood pressure, central venous pressure, right
atrial pressure, and pulmonary artery pressure (when available).
The patients were randomized by the research perfusionist using
sequentially ordered randomization codes. The randomization codes
were generated using a computerized random number generator. The pa-
tients in group 1 (treatment group) received standard care with the addition
of gNO. After termination of CPB, the gNOwas discontinued. The patients
in group 2 (control group) were treated with a strategy identical to that in
the treatment group, with the exception that they had not received gNO at
any point. The entire care team was unaware of the delivery device and
drug delivery. Only the study perfusionist was aware of the randomization
and delivery. All equipment and devices were identical.
NO Delivery
Gas was delivered using the Inovent Transport delivery device (Ikaria,
Hampton, NJ), which was calibrated according to the manufacturer’s
instructions before use. After CPB circuit set up and priming, the NO injec-
tion arm of the Inovent was incorporated into the oxygen delivery tubing.
This procedure was accomplished by simply adding reducing connectors
from the NO injector to connect the injector to the 0.25-in oxygenator
gas supply tubing. NO sampling was performed by adding a luer lock con-
nector to the gas tubing approximately 4 in. proximal to the oxygenator gas
inlet and attaching the sampling line to this connector. The gas supply to the
membrane oxygenator was as follows: oxygen/air blender plus carbon
dioxide flow meter to the Isoforane vaporizer to the Inovent injector to
NO sampling port to in-line gas filter to the membrane oxygenator. Imme-
diately before the start of CPB, the gas tubing was disconnected from the
oxygenator, and gas flow was started at 2 to 5 L/min. Delivery of NO
was initiated at 80 ppm until the return sample began to increase. At thatThe Journal of Thoracic and Capoint, the delivery of NO was reduced to 20 ppm. Once the return sample
read 20  2 ppm, the gas flow was turned off, and the tubing was recon-
nected to the oxygenator. This process ensured that NO was delivered
immediately to the oxygenator as soon as the gas flow was initiated with
the beginning of CPB.
Performance of CPB
CPB was performed using established institutional protocols and was
not altered during the study period. All patients received 30 mg/kg of meth-
ylprednisolone in the bypass prime volume. In brief, the CPB circuit con-
sisted of 0.25-in. tubing and incorporated a Capiox pediatric arterial filter.
ACapiox RX05 hollow fiber oxygenator (Terumo Cardiovascular Systems,
Ann Arbor, Mich) with a hard shell venous reservoir used for all cases. The
tubing, oxygenator, and venous reservoir were coated with Terumo’s X
Coating (Terumo Cardiovascular Systems), a proprietary biocompatible
material applied to the blood-contacting surfaces. A hemoconcentrator
was used for all cases, both during CPB and afterward, to performmodified
ultrafiltration. The prime volume was 400 to 450 mL, depending on the
starting reservoir volume. The prime volume consisted of 200 to 300 mL
of Plasma-Lyte A, 100 mL of 25% albumin, 1 g/kg mannitol, 5000 U of
heparin, 400 to 500 mg of calcium gluconate, 30 mg/kg of Solu-Medrol,
15 to 20 mEq NaHCO3, and packed red blood cells. The volume of packed
red blood cells varied by patient size and starting hematocrit. Our target he-
matocrit was>25%. The activated clotting time and heparin levels were
monitored using Medtronic’s HMS system (Medtronic, Minneapolis,
Minn). For patients with heparin requirements>6 U/mL, fresh frozen
plasma 10 mL/kg was administered before CPB and a repeat heparin
dose response was obtained. Our goal was a heparin requirement of<6
U/mL. Ascending aortic and bicaval cannulation was used for all cases.
On initiation of CPB, a left ventricular vent was inserted by way of the right
pulmonary veins. Blood gases were managed using an alpha-stat strategy.
Myocardial protection was accomplished using a cold hyperkalemic solu-
tion consisting of 1000 mL 5% dextrose, 27 mEq sodium chloride, 20 mEq
potassium chloride, 3 mEqmagnesium chloride, and 10mEq sodium bicar-
bonate, which was mixed at approximately 4:1 with blood from the CPB
circuit and delivered into the ascending aorta after placement of the aortic
crossclamp. Additionally, topical ice slush was used. The initial cardiople-
gia dose was 20 to 30 mL/kg, with additional doses (50-100 mL) given
every 20 to 25 minutes. The initial dose and the subsequent doses varied
according to patient size. No differences were found between the 2 groups
in any CPB parameters, including the mean arterial blood pressure during
CPB, flow rates, fluid balance, and ultrafiltration conduct.Sample and Data Collection
Five samples were obtained from each patient immediately before
surgery on induction of anesthesia; on admission to the pediatric CICU
after surgery; and at 12, 24, and 48 hours after surgery. The measurements
included methemoglobin, the prothrombin time, partial thromboplastin
time, complete blood count, arterial lactate, arterial blood gas, serum elec-
trolytes, creatinine, cardiac troponin I (cTnI), B-type natriuretic peptide
(BNP), interleukin [IL]-6, IL-8, and tumor necrosis factor-a. Measure-
ments of the clinical parameters were collected throughout the study
period and included fluid balance, urine output, and diuretic administra-
tion. Additionally, the ventilator settings, length of CICU and hospital
stay were recorded. Patients were followed up until discharge from the
institution.Sample Processing
The cytokine measurements (IL-6, IL-8, tumor necrosis factor-a) were
determined using commercially available assays (IBT Laboratories,
Lenexa, Kan). The serum levels of cTnI and BNP were determined using
commercially available assays (Siemens Healthcare Diagnostics,Washing-
ton, DC, and Bayer Diagnostics, Leverkusen, Germany, respectively).rdiovascular Surgery c Volume 146, Number 3 531
TABLE 1. Comparison of patient demographics and clinical data
Variable
Gaseous nitric
oxide group Placebo group P value
Gender (n) NS
Male 7 4
Female 1 4
Age (d) 191  112 216  114 NS
CPB time (min) 118  31 128  36 NS
Crossclamp time (min) 60  10 67  9 NS
Ventilator duration (h) 8.4  7.6 16.3  6.5 <.05
CICU LOS (h) 53.8  19.7 79.4  37.7 <.05
Hospital LOS (d) 5.63  2.5 5.13  1.2 NS
Data presented as n or mean  standard deviation. CPB, Cardiopulmonary bypass;
CICU, cardiac intensive care unit; LOS, length of stay; NS, not significant.
TABLE 2. Comparison of laboratory and clinical results between
study and placebo groups
Variable Nitric oxide Placebo
P
value
Postoperative fluid balance
(total mL within 48 h)
187  122 317  271 NS
Lasix (total mL within 48 h) 1.63  0.9 3.25  1.0 <.05
Chlorothiazide (mg/kg total 48 h) 0 6.3  7.4 < .05
Greatest methemoglobin (g/dL) 1.3  0.5 1.3  0.3 NS
Hemoglobin (g/dL) 11.8  1.7 9.8  0.9 <.05
Chest tube output (total mL
within 48 h)
260  44 310  131 NS
PRBC transfusion (total mL
within 48 h)
45  43 47  75 NS
Platelet transfusion (total mL
within 48 h)
0 0 NS
FFP transfusion (total mL
within 48 h)
6  18 16  30 NS
IL-6 (ng/mL)
Preoperative 3.8  3.5 3.4  2.5 NS
0 h 90.9  44.6 78.3  45.7 NS
12 h 51.5  38.7 73.3  67.0 NS
24 h 64.2  28.4 80.7  82.1 NS
48 h 31.2  30.6 39.4  48.9 NS
IL-8 (ng/mL)
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All statistical analyses were conducted using Statistical Analysis Sys-
tem, version 9.1 (SAS Institute, Cary, NC). The continuous demographic
and clinical variables listed in Table 1 were compared between the gNO
and placebo groups using the 2-independent sample t test or the Wilcoxon
2-Sample test, whichever was appropriate. Gender was compared between
the groups using Fisher’s exact test. The laboratory variables listed in
Table 2, including cTnI and BNP, were compared between the NO and pla-
cebo groups using the 2-independent sample t test or Wilcoxon 2-sample
test, as appropriate.Preoperative 60.9  28.2 39.8  39.0 NS
0 h 189.8  104.1 248.9  191.7 NS
12 h 144  133.4 85.9  59.9 NS
24 h 101.5  62.7 139.2  162.1 NS
48 h 134.2  107.0 60.4  33.7 NS
Tumor necrosis factor-a (ng/mL)
Preoperative 2.9  0.8 3.2  1.1 NS
0 h 3.2  1.5 4.1  1.6 NS
12 h 1.7  0.07 1.9  1.1 NS
24 h 1.7  1.3 3.2  2.9 NS
48 h 2.8  0.09 2.1  1.2 NS
Lactate (mmol/L)
Preoperative 0.9  0.2 0.5  0.1 NS
0 h 1.9  0.6 1.9  1.0 NS
12 h 1.5  0.4 1.5  0.5 NS
24 h 1.4  0.5 1.4  0.4 NS
48 h 1.1  0.2 1.1  0.2 NS
cTnI (ng/mL)
Preoperative 0.07  0.07 0.06  0.1 NS
0 h 50.6  37.8 54.1  15.5 NS
12 h 11.7  3.2 15.9  3.5 <.05
24 h 8.9  2.6 12.5  2.7 <.05
48 h 4.8  1.6 7.6  2.0 <.05
BNP (pg/dL)
Preoperative 24  22 100  195 NS
0 h 43  34 94  100 NS
12 h 494  222 812  300 <.05
24 h 425  154 938  511 <.05
48 h 558  535 1298  827 NS
PRBC, Packed red blood cell; FFP, fresh frozen plasma; IL, interleukin; cTnI, cardiac
troponin I; BNP, B-type natriuretic peptide; NS, not significant.RESULTS
Patient Characteristics
A total of 25 patients were eligible for participation ac-
cording to the inclusion and exclusion criteria. Of the 25 pa-
tients, 16 consented and were enrolled in the present study.
The parents or guardians of 8 patients did not provide con-
sent. One patient was disqualified after consent and ran-
domization owing to intraoperative findings of a lesion
inconsistent with the preoperative diagnosis and a change
in the operative plan. The patient characteristics are listed
in Table 1. No differences were found in age, CPB time,
crossclamp time, or surgical approach and technique. The
same 2 surgeons performed all the operations during the
study period. No patients in the study population underwent
ventriculotomy, and none were left with pulmonary insuffi-
ciency. No differences were found in the operative start
times and time of admission to the CICU. There was a pre-
ponderance of males in the present study, consistent with
the overall prevalence of congenital heart defects. No child
received additional gNO outside the study protocol. No
patients died in the present study.
The group receiving gNO had a significantly shorter du-
ration of mechanical ventilation support. The patients were
ventilated for 8.4  7.6 hours compared with 16.3  6.5
hours (P< .05), a nearly 50% reduction (Figure 1, A).
The gNO group had a 32% reduction in the length of stay in
the pediatric CICU (53.8  19.7 vs 79.4  37.7 hours,
P<.05; Figure 1, B). No differences were found in the over-
all hospital length of stay between the 2 groups (Table 1).532 The Journal of Thoracic and Cardiovascular Surgery c September 2013
FIGURE 1. A, Comparison of ventilator hours. B, Comparison of inten-
sive care unit length of stay. P<.05 for both graphs. Solid bar, placebo
group; hatched bar, gaseous nitric oxide group.
FIGURE 2. A, Comparison of cardiac troponin values. P< .05 at all
points. B, Comparison of B-type natriuretic peptide measurements.
Solid line, placebo; hatched line, gaseous nitric oxide group. *P<.05 at
12- and 24-hour points.
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effect, as indicated by the cTnI and BNP values (Table 2).
The gNO group had lower cTnI values at 12, 24, and 48
hours (P<.05; Figure 2, A). Additionally, the gNO group
had lower BNP measurements at 12 and 24 hours
(P<.05; Figure 2, B).
Overall, the postoperative fluid balance in the first 48
hours showed a trend toward an improved balance in the
gNO group but failed to achieve significance (þ187 mL
in the gNO group vs þ317 mL in the placebo group).
This finding was present even though the treatment group
received significantly less diuretic during the same period
(1.6  0.9 mg/kg vs 4.0  1.0 mg/kg intravenous furose-
mide, P<.05). Furthermore, no patients in the gNO group
received chlorothiazide; however, patients in the placebo
group received a mean total dose of 6.3  7.4 mg/kg in
the first 48 hours postoperatively (P<.05; Table 2). No dif-
ferences were found in the mean serum creatinine or blood
urea nitrogen between the 2 groups (data not shown).
The patients who received gNO during CPB had a greater
mean hemoglobin at 48 hours (11.8 1.7 vs 9.8 0.9 g/dL,The Journal of Thoracic and CaP<.05) despite no differences in chest tube output, packed
red blood cell transfusion, platelet counts or transfusion,
fresh frozen plasma transfusion, or prothrombin time or par-
tial thromboplastin time in the first 48 hours after surgery
(Table 2).
No differences were found between the 2 groups in the in-
flammatory response, as assessed by serum IL-6, IL-8, or tu-
mor necrosis factor-a levels. Additionally, no differences in
arterial blood gas measurements or arterial lactate measure-
ments were found between the 2 groups at any measurement
point (Table 2). Finally, no differenceswere seen in any other
hemodynamic variable measured, including the systolic and
diastolic blood pressure, mean arterial blood pressure, ino-
tropic score, heart rate, fluid administration, or central
venous pressure measurements throughout the study period.DISCUSSION
In the present study, we evaluated the effect of the delivery
of gNO to themembraneoxygenator of theCPBcircuit on the
postoperative outcome measures in children undergoing
cardiac surgery for congenital heart disease. Children
who received gNO during CPB had an improved postopera-
tive course,whichwas demonstrated by significantly reducedrdiovascular Surgery c Volume 146, Number 3 533
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ventilation and length of stay in the pediatric CICU.
These findings have the potential for significant clinical
effect. In the United States alone, approximately 400,000
cardiac surgical operations are performed annually, of
which 10,000 are performed in children. In nearly all cases,
these procedures induce ischemia/reperfusion injury and
generate a systemic inflammatory response syndrome. As
a result, organ function is impaired, leading to an increase
in vascular permeability, fluid retention, and significant
morbidity and potential mortality. Children appear to be
particularly susceptible to developing multisystem organ
failure as a result of these processes.7
Ischemia/reperfusion injury and systemic inflammatory
response syndrome are linked. Myocardial and pulmonary
ischemia/reperfusion injury is, in large part, an inflamma-
tory phenomenon. After a period of ischemia, reperfusion
stimulates the release of additional pro-inflammatory medi-
ators, in particular, reactive oxygen species and cytokines,
by parenchymal, endothelial, platelet, and inflammatory
cells, contributing to elevated serum levels of inflammatory
mediators. Cell death results from coagulation necrosis and
inflammatory mediator-induced apoptosis. Central to the
pathophysiology of reperfusion injury is endothelial dam-
age, resulting in impairment of the NO–cyclic guanosine
monophosphate signaling cascade and endothelial-
dependent vasodilation.8 Reperfusion injury is modulated
by supplemental gNO. This ‘‘local’’ inflammation contrib-
utes to the systemic inflammatory response syndrome by
spilling over into the systemic circulation and in so doing
‘‘contributes’’ to the systemic inflammatory response. We
believe that glucocorticoids administered before either
stimulus (inflammation or ischemia/reperfusion) attenuates
the inflammatory response. We theorized that the study re-
sults could potentially be more dramatic if the immune
system had not been primed at all, in particular, when study-
ing the markers of reperfusion injury.
NO appears to be a key link between ischemia/reperfu-
sion injury and the rate of tissue repair.9 Alterations in
NO generation appear to underpin the interrelationship of
endothelial function and inflammation.6 Although NO has
been used for pulmonary hypertension for well over a de-
cade, its role in tissue injury, apoptosis, and inflammation
was the focus of the present study and of other investiga-
tions.10 NO might play several protective roles in myocar-
dial reperfusion injury.11 NO is an important regulator of
apoptosis, capable of both inducing and preventing apopto-
sis.12 NO has been shown to inhibit platelet adhesion and
aggregation13 and is able to block monocyte adherence
and migration.14 Furthermore, NO is an inhibitor of leuko-
cyte activation, preventing neutrophil–endothelium adhe-
sion and the generation of oxygen free radicals.15
Given each of these factors, NO serves as a potential ther-
apeutic target. Hataishi and colleagues5 demonstrated that534 The Journal of Thoracic and Cardiovascular Surgbreathing NOmarkedly decreases the myocardial infarction
size and improves left ventricular function after ischemia
and reperfusion. Exogenous NO is a potent cardioprotective
agent that modulates neutrophil-mediated damage.16 Addi-
tionally, gNO appears to serve as a cardioprotective agent in
an animal model of cardiac arrest and cardiopulmonary re-
suscitation.17 Finally, although none of these investigations
specifically involved arterial delivery of gNO, such as we
used in our study, the overall theoretical basis for this deliv-
ery has been supported by several reports.18-20
The ischemia/reperfusion injury that occurs after cardiople-
gic arrest leads to myocardial injury and impaired function.
It is this specific organ injury that appears to be most affected
by the addition of gNO in our results. The mechanisms
involved in this process could include reperfusion-induced in-
flammation and apoptosis.21 Because myocardial apoptosis is
a part of normal fetal and postnatal maturation, the immature
myocardium of the infant might have an increased vulnerabil-
ity or susceptibility to apoptosis-related processes after sur-
gery, contributing to postoperative ventricular dysfunction.12
Our premise was that NO added to the circuit would have
effects distal to the entry site. This concept is inconsistent
with the current dogma regardingNOmetabolism.However,
increasing evidence has shown that NO, or NO donors, given
to patients with decreased NO bioavailability results in
decreased vascular resistance, increased blood flow, and de-
creased inflammation, and, thereby, decreased tissue dam-
age.22 This finding has been modeled in disease states
involving hemolysis, such as sickle cell disease. Specifically,
Reiter and colleagues23 have demonstrated that cell-free he-
moglobin limits NO bioavailability in patients with sickle
cell disease. Decompartmentalized hemoglobin scavenges
endogenously generated and exogenously delivered NO. A
similar phenomenon might also occur with crush injuries,
duringCPB, andwith transfusion reactions.24 The hemolysis
associated with cardiovascular surgery and NO bioavailabil-
ity was recently reviewed by Vermeulen Windsant and col-
leagues.25 An acute scavenging of NO by oxyhemoglobin
liberated by hemolysis during CPB, without regard to vascu-
lar histologic limitations, might produce the required vaso-
constriction, platelet activation, leukocyte-endothelial cell
adhesion, and oxygen free radical generation necessary to
explain the clinical phenomenon associated with CPB and
myocardial reperfusion injury. This could be compounded
by the lack of bioavailability of NO in stored and transfused
blood during the operative period.26 Although this mecha-
nism might have affected our results, we did not find direct
evidence of hemolysis in our population.
Our findings of the changes in fluid balance, BNP, and di-
uretic usage imply either an improved hemodynamic profile
or a renal effect of gNO delivery. Investigators have postu-
lated a role of NO on renal protection after ischemia and
reperfusion.27 Animal models have demonstrated that
CPB-induced ischemia/reperfusion and inflammation resultery c September 2013
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dothelial cell injury and activation and leukocyte sequestra-
tion and reduced glomerular filtration rates and creatinine
clearance.28 Additionally, models of renal ischemia/reper-
fusion injury have clearly demonstrated the role of inflam-
mation in producing tubular injury and dysfunction,
findings much more dramatic than those reported for
CPB-induced inflammation alone.29
Children who received gNO had a greater mean hemo-
globin throughout the initial postoperative period, despite
the lack of increased blood product usage. This was
a surprising finding, and we do not have a clear causative
explanation because we did not find evidence of hemolysis.
Although it might have been related to the fluid balance, the
role of gNO in this process has been supported by previous
investigations. Multiple investigators have demonstrated
the NO effects on platelet function, adhesion and aggrega-
tion in bypass and hemorrhagic shock.30 However, we did
not find a change in coagulation measurements or bleeding
in the study group, thereby mitigating any potential inter-
pretation of the effect of NO on coagulation.
Our results lend support to the speculation of a mechanis-
tic construct. CPBwith cardioplegic arrest leads to ischemia
and reperfusion injury of the myocardium, endothelial dys-
function, and changes in vasodilatory response, which are
exacerbated by the imbalance of NO bioavailability associ-
ated with hemolysis and stored blood transfusion. Finally,
renal injury occurs through both inflammation and hemody-
namic compromise, leading to a decreased glomerular
filtration rate and fluid imbalance.
Our study had important limitations. First, our study was
a pilot investigation and, therefore, had limited subjects.
Additionally, we chose to investigate a single lesion, tetral-
ogy of Fallot. The effect of this unique anatomy, specifically
with regard to right ventricular structure and function, is un-
known. All patients in the present study received systemic
steroids. Finally, we did not have access to biopsy speci-
mens from the myocardium or kidneys, which would have
aided in clarifying the proposed mechanisms of action.
Despite these limitations, our results have demonstrated
a robust biochemical and clinically meaningful outcome.
In conclusion, we evaluated the effect of gNO delivery to
the membrane oxygenator of the CPB circuit on the postop-
erative outcomemeasures in pediatric patients with congen-
ital heart disease. The children who received gNO during
CPB had an improved postoperative course, as demon-
strated by a shorter length of stay in the pediatric CICU,
a shorter duration of mechanical ventilation requirement,
and improved indexes of myocardial injury and function.
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